Search
Sanofi Strengthens Respiratory Product Pipeline with $1.6 Billion Acquisition of Vicebio
3 week ago /
Read about 0 minute
Author：小编
Sanofi has announced the acquisition of British biotechnology firm Vicebio for a total of $1.6 billion, aimed at bolstering its respiratory product portfolio. The transaction comprises an initial payment of $1.15 billion, with potential additional milestone payments totaling up to $450 million. This acquisition grants Sanofi access to Vicebio's innovative molecular tweezers technology platform, a pivotal asset in the development of cutting-edge vaccines. The deal also enables Sanofi to acquire experimental vaccines and technologies that will expedite the research and development of vaccines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
